Latest Breaking News On - தொடர்ந்து சிகிச்சை - Page 1 : comparemela.com

Onward Therapeutics takes first steps of its buy and build strategy Startupticker ch

Headed by the successful biotech entrepreneur Grace Yeh, Onward Therapeutics pursues a buy and build strategy with the goal to identify and develop innovative medicines for the treatment of cancer. The company which was founded in 2020 and is based at Biopôle has now closed the first contracts with two biotech start-ups. Onward Therapeutics acquires licenses for potential development candidates and investing in their partners with platform technologies. The company is led by an experienced team.Grace Yeh, President and CEO of Onward Therapeutics was Founder, President and Chief Executive Officer of PharmaEngine, Inc., a publicly traded commercial stage oncology company headquartered in Taipei, Taiwan with a wholly owned subsidiary in Paris, France. Its market capitalization on the Taipei Exchange exceeded US$1 billion.

T ai peiFrance generalAlain herreraPharmaengine incTaipei exchangeBiomunex pharmaceuticalsOnward therapeuticsGrace yehChief executive officerWednesday onwardChief medical officerடி ஐ பேய்பிரான்ஸ் ஜநரல்அலன் ஹெர்ரெராதைப்பே பரிமாற்றம்தொடர்ந்து சிகிச்சை

EMERCell Signs Strategic Partnership with Onward Therapeutics for the Development of its NK Cell Therapy Technology

(1) EMERCell, a biotechnology company developing immunotherapies and cell-based therapies for oncology targets through to pharmaceutical development, announces the signature of a strategic partnership with Onward Therapeutics. The significant investment, of a confidential amount, will be made in three instalments that will allow EMERCell to reach the first human clinical trials. We are delighted to partner with Onward Therapeutics, whose teams have recognized expertise in the development of new drugs in oncology and with whom we have strong synergies. Their participation is a recognition of our expertise and will allow us to accelerate our development, said Patrick Henno, founder and Chairman of EMERCell.

Patrick hennoKostenloser wertpapierhandelCaroline carmagnolUniversity hospital of montpellierInstitute of regenerative medicineSaint eloi university hospital centerUniversity of montpellierOnward therapeuticsUniversity hospitalRegenerative medicineNatural killerOccitanie regionபல்கலைக்கழகம் மருத்துவமனை ஆஃப் மான்ட்பெல்லியர்நிறுவனம் ஆஃப் மீளுருவாக்கம் மருந்துபல்கலைக்கழகம் ஆஃப் மான்ட்பெல்லியர்தொடர்ந்து சிகிச்சை

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy News provided by Share this article Share this article LAUSANNE, Switzerland, Feb. 17, 2021 /PRNewswire/ Onward Therapeutics SA (Onward) announced today the execution of a strategic investment in EMERCell SAS, Montpellier, France, a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells. The undisclosed amounts of the equity investment in three instalments, allow Onward to become the majority shareholder. Dr. Alain Herrera, Chief Medical Officer of Onward, has been elected Chairperson of the Board of EMERCell. In the era of cancer immunotherapy, NK cells are one of the immune cells that can be harnessed, along with antibodies or genetic modifications to kill tumor cells. One major advantage of EMERCell s technology is its versatility in offering allogeneic, instead of autologous treatment by CAR-T or CAR-NK cell therapy. Onwar

T ai peiFrance generalSwitzerland generalPatrick hennoAlain herreraBiomunex pharmaceuticalsChief medical officerOnward therapeuticsOnward therapeutics saHealth care amp hospitalsBanking amp financial servicesMedical pharmaceuticalsVenture capitalடி ஐ பேய்பிரான்ஸ் ஜநரல்சுவிட்சர்லாந்து ஜநரல்

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

T ai peiFrance generalSwitzerland generalPatrick hennoAlain herreraBiomunex pharmaceuticalsChief medical officerOnward therapeuticsடி ஐ பேய்அலன் ஹெர்ரெராதலைமை மருத்துவ அதிகாரிதொடர்ந்து சிகிச்சை

Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology

LAUSANNE, Switzerland, Feb. 16, 2021 /PR Newswire/ Onward Therapeutics SA announced today the execution of a worldwide exclusive license and co-development agreement with Biomunex.

United statesFrance generalSwitzerland generalT ai peiUnited kingdomPierre emmanuel gerardBiomunex pharmaceuticalsOnward therapeuticsஒன்றுபட்டது மாநிலங்களில்பிரான்ஸ் ஜநரல்சுவிட்சர்லாந்து ஜநரல்டி ஐ பேய்ஒன்றுபட்டது கிஂக்டம்பியர் இம்மானுவேல் ஜெரார்ட்தொடர்ந்து சிகிச்சை